Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12984920 | 0.89 | MEN1 (0.53) | MEN1KMT2ANPC1RAB9ADHFR | |
| SCHEMBL30662759 | 0.89 | MEN1 (0.53) | MEN1KMT2ANPC1RAB9ADHFR | |
| SCHEMBL30451947 | 0.87 | SIGMAR1 (0.46) | MEN1KMT2ANPC1RAB9ATP53 | |
| SCHEMBL3715438 | 0.87 | SIGMAR1 (0.46) | MEN1KMT2ANPC1RAB9ATP53 | |
| SCHEMBL11069340 | 0.82 | SIGMAR1 (0.61) | MEN1KMT2ANPC1RAB9ADRD4 | |
| Hydrochloric Acid SCHEMBL11078532 | 0.80 | SIGMAR1 (0.59) | MEN1KMT2ANPC1RAB9ADRD4 | |
| SCHEMBL31134754 | 0.80 | ACHE (0.66) | MEN1KMT2ADRD4PNMT | |
| SCHEMBL10978742 | 0.80 | ACHE (0.66) | MEN1KMT2ADRD4PNMT | |
| SCHEMBL29883119 | 0.79 | KMT2A (0.63) | MEN1KMT2ANPC1RAB9ADHFR | |
| SCHEMBL1038680 | 0.79 | KMT2A (0.63) | MEN1KMT2ANPC1RAB9ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-107207532-B | Nitroimidazole derivatives against tuberculosis | 南京明德新药研发股份有限公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-109689645-A | Cyanoindole quinoline derivant as NIK inhibitor | 杨森制药有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-106467537-B | A kind of substituted amides compound and purposes | 沈阳中化农药化工研发有限公司 | 2019-03-19 | — | — | CN | disclosed |
| CN-106467538-B | A kind of substituted tetrahydro isoquinoline compound and purposes | 沈阳中化农药化工研发有限公司 | 2019-03-05 | — | — | CN | disclosed |
| CN-106946909-A | The nitro imidazole derivatives for the treatment of pulmonery tuberculosis disease | 南京明德新药研发股份有限公司 | 2017-07-14 | — | — | CN | disclosed |
| US-8563566-B2 | Naphthyridine derivatives as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2013-10-22 | — | — | US | disclosed |
| US-20110082130-A1 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | LIGAND PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082130-A1 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | LIGAND PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082130-A1 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | LIGAND PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-0321191-B1 | Heterocyclic-substituted quinoline-carboxylic acids | PFIZER (US) | 1994-11-02 | — | — | EP | disclosed |
| US-5214051-A | Thiazolyl and oxazolyl[5,4-c]piperidyl-substituted quinolone-carboxylic acid and related analogs thereof having antibacterial properties are disclosed | PFIZER INC. (US) | 1993-05-25 | — | — | US | disclosed |
| US-5037834-A | Heterocycylic-substituted quinoline-carboxylic acids | PFIZER INC. (US) | 1991-08-06 | — | — | US | disclosed |
| WO-1989005643-A1 | HETEROCYCLIC-SUBSTITUTED QUINOLINE-CARBOXYLIC ACIDS | PFIZER INC. (US) | 1989-06-29 | — | — | WO | disclosed |
| EP-0321191-A2 | Heterocyclic-substituted quinoline-carboxylic acids | PFIZER INC. (US) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | MEN1 531/4885KMT2A 3061/4885NPC1 3135/4885 |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | MEN1 2216/4885KMT2A 923/4885NPC1 4421/4885 |
| US-20110082130-A1 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | HRH3, HRH4, HRH1 | MEN1 2317/4885KMT2A 566/4885NPC1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.